NDC product
benazepril hydrochloride and hydrochlorothiazide
NDC 0574-0229 · Padagis US LLC
Key facts
| Product NDC | 0574-0229 |
|---|---|
| Proprietary name | benazepril hydrochloride and hydrochlorothiazide |
| Nonproprietary name | benazepril hydrochloride and hydrochlorothiazide |
| Substances | BENAZEPRIL HYDROCHLORIDE, HYDROCHLOROTHIAZIDE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Padagis US LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA020033 |
| Pharmacologic classes | Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Decreased Blood Pressure [PE], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS] |
| Marketing start | Apr 7, 2019 |
| Marketing end | Sep 30, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory